FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer is a research paper published in Proceedings of the National Academy of Sciences (2016). On theSindex it has a DataRank of 0.784. It has been cited 185 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.784
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →DOD | Congressionally Directed Medical Research Programs
Grant: W81XWH-14-1-0326
Breast Cancer Research Foundation
Grant: BCRF
American Association for Cancer Research
Grant: SU2C-AACR-DT0409
HHS | NIH | National Cancer Institute
Grant: Breast Cancer SPORE
HHS | NIH | National Cancer Institute
Grant: P30CA125123
Susan G. Komen for the Cure
Grant: PG12221410
Susan G. Komen for the Cure
Grant: SAC110012
NCI NIH HHS
Grant: P50 CA186784
NCI NIH HHS
Grant: P01 CA080111
NIAID NIH HHS
Grant: P30 AI036211
NCI NIH HHS
Grant: P50 CA058183
NCRR NIH HHS
Grant: S10 RR024574
MeSH Terms
Keywords
Additional file 1 of AGR2 and FOXA1 as prognostic markers in ER-positive breast cancer
Additional file 1 of AGR2 and FOXA1 as prognostic markers in ER-positive breast cancer
Additional file 2 of AGR2 and FOXA1 as prognostic markers in ER-positive breast cancer
Additional file 2 of AGR2 and FOXA1 as prognostic markers in ER-positive breast cancer
Additional file 3 of AGR2 and FOXA1 as prognostic markers in ER-positive breast cancer
Additional file 3 of AGR2 and FOXA1 as prognostic markers in ER-positive breast cancer
Additional file 4 of AGR2 and FOXA1 as prognostic markers in ER-positive breast cancer
Additional file 4 of AGR2 and FOXA1 as prognostic markers in ER-positive breast cancer
Additional file 5 of AGR2 and FOXA1 as prognostic markers in ER-positive breast cancer
Additional file 5 of AGR2 and FOXA1 as prognostic markers in ER-positive breast cancer
Additional file 1 of Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial
Additional file 1 of Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial
Additional file 4 of Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial
Additional file 4 of Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial
Additional file 5 of Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial
Additional file 5 of Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial
Additional file 6 of Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial
Additional file 6 of Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial
Additional file 3 of Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial
Additional file 2 of Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial